Skip to content

US · LPCN · BIOTECHNOLOGY

Lipocine Inc. (LPCN) intrinsic value and stock valuation

$1.48as of 2026-11-21 · Mkt cap 12.59M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Lipocine Inc. DCF and intrinsic value

InvestorsCraft values LPCN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LPCN’s statements →

Lipocine Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Salt Lake City, UT 84108 lipocine.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.98M
20112025
Net income
-$-9.63M
20112025
Free cash flow
-$-9.76M
20112025
Total equity
$14.5M-1.1% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.98M$11.2M-$-2.85M$500K$16.1M
Operating income-$-10.37M-$-1.16M-$-17.93M-$-12.12M$3.15M
Net income-$-9.63M$10K-$-16.35M-$-10.76M-$-630K
EPSd-$-1.69M$1.85K-$-3.1M-$-2.05M-$-122.33K
Operating cash flow-$-9.76M-$-1.22M-$-11.87M-$-11.97M-$-4.41M
Capital expenditure$0.00-$-90K-$-10K-$-130K-$-10K
Free cash flow-$-9.76M-$-1.31M-$-11.88M-$-12.1M-$-4.42M
Total assets$17M$22.5M$23M$37.5M$52.5M
Total debt$450K$0.00$0.00$0.00$2.31M
Net debt-$-4.76M-$-6.21M-$-4.77M-$-3.15M-$-640K
Total equity$14.5M$21M$20.4M$35.6M$45.6M
Cash and short-term investments$14.9M$21.6M$22M$32.5M$44.6M
Income statement
20252024202320222021
Revenue$1.98M$11.2M-$-2.85M$500K$16.1M
Cost of revenue$8.58M$0.00$10.2M$8.56M$7.67M
Gross profit-$-6.61M$11.2M-$-13.03M-$-8.06M$8.48M
Research and development expenses$0.00$7.35M$0.00$0.00$0.00
Selling, general and administrative expenses$3.76M$5M$4.9M$4.06M$5.33M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$3.76M$12.4M$4.9M$4.06M$5.33M
Cost and expenses$12.4M$12.4M$15.1M$12.6M$13M
Interest income$740K$1.15M$1.37M$570K$70K
Interest expense$0.00$0.00$0.00$30K$200K
Depreciation and amortization$60K$40K$30K$10K$0.00
Ebitda-$-9.57M$50K-$-16.32M-$-10.72M-$-430K
Operating income-$-10.37M-$-1.16M-$-17.93M-$-12.12M$3.15M
Total other income/expenses, net$740K$1.16M$1.58M$1.36M-$-3.78M
Income before tax-$-9.63M$10K-$-16.35M-$-10.76M-$-630K
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-9.63M$10K-$-16.35M-$-10.76M-$-630K
Weighted average shares outstanding$5.45M$5.34M$5.27M$4.99M$3.3M
Weighted average diluted shares outstanding$5.71M$5.42M$5.27M$5.26M$5.15M
Balance sheet
20252024202320222021
Cash and short-term investments$14.9M$21.6M$22M$32.5M$44.6M
Net receivables$10K$120K$50K$660K$250K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$16.9M$22.3M$22.9M$34.1M$46.4M
Property, plant and equipment, net$100K$170K$120K$130K$10K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$3.25M$2.02M
Total non-current assets$130K$190K$140K$3.41M$6.1M
Total assets$17M$22.5M$23M$37.5M$52.5M
Accounts payable$970K$270K$1.4M$600K$1.29M
Short-term debt$450K$0.00$0.00$0.00$2.31M
Deferred revenue$0.00$320K$0.00$0.00$0.00
Total current liabilities$2.53M$1.51M$2.63M$1.68M$5.62M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$230K$1.3M
Capital lease obligations$450K$0.00$0.00$0.00$0.00
Total liabilities$2.53M$1.51M$2.63M$1.91M$6.91M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-209.4M-$-199.77M-$-199.78M-$-183.43M-$-172.67M
Accumulated other comprehensive income (loss)$0.00$10K$10K-$-20K-$-20K
Total equity$14.5M$21M$20.4M$35.6M$45.6M
Total investments$9.72M$15.4M$17.3M$32.6M$43.7M
Total debt$450K$0.00$0.00$0.00$2.31M
Net debt-$-4.76M-$-6.21M-$-4.77M-$-3.15M-$-640K
Cash flow statement
20252024202320222021
Net income-$-9.63M$10K-$-16.35M-$-10.76M-$-630K
Depreciation and amortization$60K$40K$30K$10K$0.00
Stock-based compensation$240K$410K$650K$640K$600K
Change in working capital-$-240K-$-960K$2.01M-$-920K-$-4.59M
Accounts receivable$110K-$-70K$740K$380K-$-250K
Inventory$0.00$0.00$0.00-$-380K$250K
Accounts payable$700K-$-1.12M$800K-$-690K-$-310K
Net cash provided by operating activities-$-9.76M-$-1.22M-$-11.87M-$-11.97M-$-4.41M
Investments in property, plant and equipment$0.00-$-90K-$-10K-$-130K-$-10K
Acquisitions, net$0.00$0.00$0.00-$-14.29M$43.8B
Net cash used for investing activities$5.89M$2.45M$13.1M$14.3M-$-43.78M
Common stock issued$2.87M$210K$400K$0.00$30.3M
Common stock repurchased$0.00$0.00$0.00-$-20K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$2.87M$210K$400K-$-2.13M$26.9M
Net change in cash-$-1M$1.43M$1.62M$200K-$-21.27M
Cash at end of period$5.21M$6.21M$4.77M$3.15M$2.95M
Operating cash flow-$-9.76M-$-1.22M-$-11.87M-$-11.97M-$-4.41M
Capital expenditure$0.00-$-90K-$-10K-$-130K-$-10K
Free cash flow-$-9.76M-$-1.31M-$-11.88M-$-12.1M-$-4.42M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Lipocine Inc.

        Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.

        CEO
        Mahesh V. Patel
        Employees
        14
        Beta
        0.44

        Explore

        Frequently asked questions

        What is the intrinsic value of Lipocine Inc. (LPCN)?

        InvestorsCraft does not currently publish an intrinsic value for LPCN. How the IC value is calculated.

        Is LPCN undervalued?

        InvestorsCraft does not publish an undervaluation signal for LPCN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.